

Special Issue

Development of Biomarker-Driven Targeted Therapies in Cancers

Message from the Guest Editor

We are pleased to invite you to submit articles to our Special Edition entitled “Biomarker-Driven Targeted Therapies in Cancers”. Significant progress has been made in recent decades for certain cancer types where specific molecular alterations drive cancer progression. The development of imatinib targeting BCR-ABL, c-KIT, and PDGFRA revolutionized the treatment of chronic myeloid leukemia and GIST and paved the way for modern targeted therapies. As a result of biomarker-driven targeted therapies, the prognosis of malignancies such as HER-2 positive breast cancers and BRAF-mutated melanoma has improved greatly. However, elucidating signaling networks for many other malignancies has been more challenging, with constellations of signaling pathways often being involved, making the development of targeted therapies more difficult for certain tumors. Thus, a multi-pronged targeted approach may be needed with exploration of targets beyond those found by next-generation sequencing. This Special Issue aims to describe current research surrounding the development of the next generation of biomarker-driven targeted therapies for cancer.

Guest Editor

Dr. Anne Mary Noonan

Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (10 February 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/118005

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).